Bank Of Montreal Atea Pharmaceuticals, Inc. Transaction History

Bank Of Montreal

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jun 13, 2024	BUY	$3.0 - $4.97 $44,076 - $73,019	14,692 New	14,692 $49,000
Q4 2021 Feb 11, 2022	SELL	$7.67 - $44.59 $276,933 - $1.61 Million	-36,106 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $770,140 - $1.27 Million	36,106 New	36,106 $1.17 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $288M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

Stay updated on Bank Of Montreal with notifications on news.